Klotho Neurosciences (KLTO) witnessed an astonishing 800% increase in stock value on June 9, 2025, after revealing positive results from pre-clinical studies. The company’s investigations indicated ...

Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics Klotho CEO Dr. Joseph Sinkule ...

The Company enlists industry veteran Dr. Bret Barnes to oversee the development of new diagnostic offerings NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (KLTO) ("Klotho" or the ...

Biogenetics company Klotho Neurosciences has announced plans to acquire assets from Turn Biotechnologies, marking a move in the development of longevity therapeutics. Turn Biotechnologies is focused ...

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy ...

Renewed interest in a protein called klotho is pervading the scientific world. Klotho is a known anti-inflammatory protein that also contains anti-aging properties. In this two-part series, we will ...

Klotho expects to complete a prototype version of the assay in 2026, after which it plans to commercialize a more efficient and cost-effective diagnostic offering. The company said the platform could ...

An international study has shown that increasing levels of the Klotho protein in mice extends lifespan and improves both physical and cognitive health when aging. An international study led by the ...

NEW YORK, Oct. 7, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho", or "the Company") today announced that its Letter of Intent with Turn Biotechnologies was allowed to expire ...